Edecesertib

CAS No. 2408839-73-4

Edecesertib( —— )

Catalog No. M35644 CAS No. 2408839-73-4

Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Edecesertib
  • Note
    Research use only, not for human use.
  • Brief Description
    Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).
  • Description
    Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    IRAK
  • Recptor
    IRAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2408839-73-4
  • Formula Weight
    435.45
  • Molecular Formula
    C22H22FN7O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (229.65 mM; Ultrasonic )
  • SMILES
    N([C@@H](C#N)C)C=1C=C(C=2N3C(=CC2)C=C(C#N)C=N3)N=CC1C(NC[C@H](C(C)(C)O)F)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6.
molnova catalog
related products
  • PF-06650833

    PF-06650833 (PF06650833) is a potent and selective IRAK4 inhibitor with IC50 of 0.2 nM.

  • PF-05387252

    A potent, selective IRAK4 inhibitor with IC50 of 1.3 nM, 200-fold selectivity over IRAK1 (IC50=290 nM).

  • CA-4948

    CA-4948 (AU-4948) is a novel potent, selective, orally bioavailable IRAK4 inhibitor.